Software as a Medical Device (SaMD) in the European Market

Software is playing an increasingly central role in healthcare delivery, from diagnostic support tools to remote patient monitoring and clinical decision systems. As a result, software solutions are no longer treated as standalone digital tools, instead, many are now regulated as medical devices in the European Union.

For companies developing or commercialising Software as a Medical Device (SaMD), understanding how these solutions are classified and regulated under EU frameworks is essential for successful market entry. This article explains how software is regulated as a medical device in Europe, including classification rules, regulatory requirements, and what companies need to consider when entering the market.

What is Software as a Medical Device (SaMD)?

Software as a Medical Device refers to software that performs a medical function without being part of a physical medical device.

In the EU, software is considered a medical device if it is intended to:

• Support diagnosis or treatment decisions
• Monitor patient health or physiological processes
• Influence or control the performance of a medical device
• Function as an accessory to a medical device

Note: If software meets these criteria, it must comply with EU medical device regulations and obtain CE marking before being placed on the market.

How is SaMD regulated in the European Union?

Medical device software in Europe is regulated under the Medical Device Regulation (MDR), which establishes strict requirements for safety, performance, and clinical evaluation. The MDR introduced significant changes compared to previous frameworks, particularly in how software is classified and reviewed.

Key requirements include:

• Demonstrating clinical evidence and performance
• Implementing quality management systems
• Ensuring ongoing monitoring and post‑market surveillance
• Maintaining documentation and traceability throughout the product lifecycle

How are software medical devices classified?

In the EU, medical devices are grouped into four classes based on risk:

• Class I (low risk)
• Class IIa
• Class IIb
• Class III (high risk)
  
  

The classification determines the level of regulatory scrutiny required to obtain CE marking. For software, classification is primarily determined by Rule 11 under the MDR, which focuses on how the software impacts clinical decisions.

What does MDR Rule 11 mean for SaMD?

Rule 11 introduced a major shift in how software is classified in the EU. In general terms:

• Software used for diagnostic or therapeutic decision‑making is classified as at least Class IIa
• Software that can lead to serious health consequences may be classified as Class IIb or Class III
• Software used for monitoring physiological processes is also typically Class IIa
• Only low‑risk applications that do not influence clinical decisions may remain Class I

What this means that many software solutions that were previously considered low risk are now classified at a higher level and subject to stricter regulatory requirements.

Which software solutions may remain Class I?

Some software applications can still fall under Class I if they do not directly influence clinical decisions or patient outcomes. Such examples include, but are not limited to:

• Wellness or fitness applications without medical claims
• Non‑critical monitoring tools that are not used for diagnosis
• Software used for general data collection without clinical interpretation
• Applications that support lifestyle improvements rather than medical treatment
  
  

However, it's important to note that manufacturers must clearly demonstrate that their software does not fall under higher‑risk categories.

What are the key regulatory requirements for SaMD?

For software classified as a medical device, companies must comply with several important requirements:

1) CE marking and conformity assessment: most SaMD solutions require assessment by a Notified Body, depending on the classification level.

2) Quality management systems: manufacturers must implement structured processes to ensure product safety, performance, and compliance throughout the lifecycle.

3) Clinical evaluation: companies must demonstrate that the software performs as intended and provides clinical benefit.

4) Unique Device Identification (UDI): each device must be traceable through a unique identification system covering its entire lifecycle.

5) Post‑market surveillance: manufacturers must continuously monitor product performance and report issues or risks.

Bonus read: European Medical Device Regulations

Why is MDR important for software companies?

The MDR significantly increased the regulatory burden because, for many SaMD companies, this means moving from self‑certification to third‑party assessment, increased costs and longer timelines for market entry, as well as greater focus on documentation and compliance processes. At the same time, stricter regulation also increases trust in digital health solutions and strengthens the overall market.

What does this mean for companies entering Europe?

For companies developing SaMD solutions, entering the European market requires early preparation. Key considerations include:

• Assessing the correct classification under MDR
• Identifying the appropriate Notified Body
• Building compliance into product development from the start
• Planning for regulatory timelines and resource requirements

Bonus read: How the MDR and UKCA regulations will impact your sales in Europe

Key Takeaways

• Software can be regulated as a medical device in the EU depending on its intended use
• MDR introduced stricter rules, especially through classification Rule 11
• Many software solutions now require Notified Body assessment
• Compliance involves CE marking, clinical evidence, and lifecycle management
• Early regulatory planning is essential for successful European market entry